TBE/iStock Editorial via Getty Images
Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue degraders (MGDs), including MRT-6160, for autoimmune disease.
Pursuant to the deal, Novartis (NVS) will
